KZIA Stock Summary and Trading Ideas (Kazia Therapeutics Limited - American Depositary Shares | NASDAQ:KZIA)

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Kazia Therapeutics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol KZIA.

As of July 24, 2026, KZIA stock price declined to $12.26 with 315,935 million shares trading.

KZIA has a beta of 2.60, meaning it tends to be more sensitive to market movements. KZIA has a correlation of 0.07 to the broad based SPY ETF.

KZIA has a market cap of $140.09 million. This is considered a Micro Cap stock.

In the last 3 years, KZIA traded as high as $79.00 and as low as $2.86.

The top ETF exchange traded funds that KZIA belongs to (by Net Assets): APIE.

KZIA has outperformed the market in the last year with a return of +23.1%, while the SPY ETF gained +17.7%. However, in the most recent history, KZIA shares have underperformed the stock market with its stock returning 0.0% in the last 3 month period and -9.6% for the last 2 week period, while SPY has returned +3.8% and -2.1%, respectively.

KZIA support price is $12.31 and resistance is $13.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KZIA shares will trade within this expected range on the day.